PGEN Stock Analysis Today
Updated Nov 6, 2026 · trends, key levels, insider activity and news
Is PGEN bullish or bearish today?
Daily trend: Downtrend (confirmed) — turns up above $8.98
SEPT signal: Distribution · Strong Bearish
Research grade: B · fair value $5.42 (+211.0%)
PGEN trend by timeframe
| Daily | Downtrend (confirmed) |
|---|---|
| 4 hour | Strong Bearish |
| 1 hour | Strong Bearish |
| 15 min | Leaning Bullish |
| 5 min | Strong Bullish |
Trends are calculated from price structure and update during market hours.
PGEN support and resistance levels
Resistance (above)
$4.468 touches
$5.1110 touches
$5.967 touches
Support (below)
$3.5120 touches
Upside zones: $5.15 / $5.36 / $5.56
See all levels on the live chart →Insider and institutional activity
Insiders
Sell30-day buys / sells
1 / 630-day net
—Hedge fund holders
176Latest PGEN news and filings
- AnalystBenzinga
Citizens keeps Market Outperform on Precigen, lifts target to $12
Citizens repeated its Market Outperform rating on Precigen and raised its price target to $12. The change reflects the firm's updated view on the stock.
- SEC FilingSECPrecigen, Inc. filed a report on a major company event (Form 8-K)
Form 8-K tells shareholders about important events such as deals, leadership changes or results.
- AnalystCitigroup
Citigroup kept its Market Outperform rating on Precigen (PGEN) with a price target of $12.
- EarningsBenzinga
Precigen holds Q3 2026 earnings call
Precigen discussed its third-quarter 2026 results on an earnings call. The headline provides no figures or details from the call.
- EarningsFiscal.ai
Precigen Posts Q3 2026 Results
The company released its quarterly numbers for the period ending in 2026's third quarter. The filing covers its latest performance.
- EarningsBenzinga
Precigen's quarterly profit and revenue top analyst expectations
The company posted third-quarter per-share earnings of $0.08 versus a $0.07 estimate. Revenue reached $74.148 million, ahead of the $71.558 million projection.
- ProductFiscal.ai
Precigen stock falls after rival RRP therapy approved
A competing treatment for recurrent respiratory papillomatosis received approval, and Precigen shares moved lower afterward. The headline gives no further details on the rival product or the size of the decline.
Live PGEN chart with trend icons on every timeframe, key levels, dark pool and options flow, news alerts, and Ask GOAX for a full analysis on demand.
Start free 7-day trialFrequently asked questions
Is PGEN bullish or bearish today?
PGEN daily trend: Downtrend (confirmed) — turns up above $8.98. SEPT signal: Distribution (Strong Bearish). Updated Nov 6, 2026.
What is PGEN's trend on each timeframe?
Daily: Downtrend (confirmed); 4 hour: Strong Bearish; 1 hour: Strong Bearish; 15 min: Leaning Bullish; 5 min: Strong Bullish.
What are PGEN support and resistance levels?
Support: $3.51. Resistance: $4.46, $5.11, $5.96. Last price $4.22.
Are insiders buying or selling PGEN?
Insider signal: Sell. Last 30 days: 1 buys, 6 sells. 176 hedge funds hold PGEN.
What is the latest news on PGEN?
Nov 5, 2026: Citizens keeps Market Outperform on Precigen, lifts target to $12 · Nov 4, 2026: Precigen, Inc. filed a report on a major company event (Form 8-K) · Nov 5, 2026: Citigroup kept its Market Outperform rating on Precigen (PGEN) with a price target of $12.